Background: Studies on B-cell subtypes and V(D)J gene usage of B-cell re-
Methods: We selected 16 ABOi KT patients with accommodation (ABOiA), 6
ABOc stable KT patients (ABOcS), and 6 ABOi KT patients with biopsyproven acute antibody-mediated rejection (ABOiR) at day 10, whose graft tissue samples had been stored in the biorepository between 2010 and 2014. Complete transcriptomes of graft tissues were sequenced and analyzed through RNA sequencing (RNA-seq). The international ImMunoGeneTics information system (IMGT®) was used for in-depth comparison of V(D)J gene segment usage.
Results:
The mean age of the 28 KT recipients was 43.3 ± 12.8 years, and 53.6% were male. By family, IGHV3, IGHJ4, IGLV2, and IGLJ3 gene segments were most frequently used in all groups, and their usage was not statistically different among the three patient groups. While IGKV3 was most frequently used in both the ABOiA and ABOiR groups, IGKV1 was most commonly used in the ABOcS group. In addition, while IGKJ1 was most commonly used in the ABOiA and ABOcS groups, IGKJ4 was most frequently used in the ABOiR group. According to individual gene segments, IGHV4-34 and IGHV4-30-2 were more commonly used in the ABOiR group than in the ABOiA group, and IGHV6-1 was more commonly used in the ABOcS group than in the ABOiR group. IGLV7-43 was more commonly used in the ABOcS group than in the ABOi group. However, technical variability, small sample size, and potential confounding effects of Rituximab or HLA mismatching are limitations of our study. Introduction: Acute and chronic allograft rejection are major problems in kidney transplantation. Identifying differences among individuals at the genomic level might help us to understand the rationale of tissue and organ rejection. The aim of this study is to identify the copy losses and gains in the genomes of patients experienced rejection in acute and chronic terms.
Materials and Methods:
This study was designed as a retrospective single center study. A total of 24 pediatric renal transplant patients (F/M:10/14) were enrolled in the study. Patients were divided into 3 groups which are 8 kidney transplantation patients without rejection, 8 patients with acute rejection and 8 patients with chronic rejection. Agilent SurePrint G3 Human CGH 60K arrays were used to identify genome wide copy number variations.
Results: Mean transplant age of the non-rejection group, acute rejection, and chronic rejections patients were 15.8±4.2, 13.2±2.7, 16.4±3.8 years respectively. Average rejection time for acute and chronic rejection patients was 16.9±9.7 and 26.4±6.7 months, respectively. Results of the aCGH analysis showed that copy number losses were detected on chromosomes 1q42.2-q42.3, 2q13, 4q31.1, 7q11.23, 11q13.2, 14q11.2, 20q13.32, and copy number gains were detected on chromosomes 1p36. 13, 1p32.3, 2p24.1, 2p21, 3q23, 5p13.2, 11q13.2, 12q24.21, 13q12.12, 16p11.2, 18p11.31, 19q13.43, 20p13, 20q11.21, 21q22 .12, 21q22.2. Copy number variations were detected in patients with acute and chronic kidney rejection group but not in the non-rejection group.
Discussion: The management of acute and chronic allograft transplantation rejection is one of the major concerns during the follow up of transplantation patients. Nevertheless standardized protocols and well tuned immunosuppressant therapies are used in transplant patients; interindividual differences can cause different responses to drugs. In this study, we identified several genomic loci that show differences in terms of copy number state among patient groups. 18p11.31 is one of the loci identified in this study. TGIF1 gene within this region was reported to be over-expressed previously in kidney transplantation patients who experienced chronic rejection, which supports our finding that overexpression could be due to gain detected.
Conclusion:
In this study, we identified copy number differences among kidney transplantation patients which might be important for the short and long term graft survival. Each region and genes within these regions could be individual possible biomarker to predict graft health.
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